AIM’s Latest Newsletter: The Research Edition, July 2023
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
Melanoma Research
08/01/2023
AIM’s Latest Newsletter: The Research Edition, July 2023
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
|
05/30/2023
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
|
|
02/28/2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)– The applications are based on results from the Phase 3 CheckMate -76K trial,…
|
|
01/27/2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
|
01/26/2023
A Letter From Our Vice President | January 2023
Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
|
01/26/2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
|
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
12/08/2022
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
|
|
11/11/2022
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
|
|
05/25/2022
Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
|
Recent Posts
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
Jan. 13, 2026